BFM
DRUG

Boothbay Fund Management’s Bright Minds Biosciences DRUG Stock Holding History

Boothbay Fund Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Buy
51,290
+3,800
+8% +$306K 0.05% 400
2025
Q4 		$3.71M Buy
47,490
+19,371
+69% +$1.29M 0.06% 386
2025
Q3 		$1.71M Buy
28,119
+8,955
+47% +$348K 0.02% 629
2025
Q2 		$500K Hold
19,164
– – 0.01% 902
2025
Q1 		$691K Sell
19,164
-25,416
-57% -$930K 0.02% 750
2024
Q4 		$1.61M Buy
+44,580
New +$1.57M 0.04% 496
2022
Q3 		– Sell
-2,208
Closed -$9K – 2322
2022
Q2 		$9K Hold
2,208
– – ﹤0.01% 2197
2022
Q1 		$17K Hold
2,208
– – ﹤0.01% 2227
2021
Q4 		$35K Buy
+2,208
New +$49.1K ﹤0.01% 1790

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Boothbay Fund Management's DRUG Position: Q1 2026 in Review

Boothbay Fund Management increased its Bright Minds Biosciences (DRUG) stake by 8% in Q1 2026, buying an estimated $306K and bringing the position to 51,290 shares worth $3.74M. The position accounts for 0.05% of the portfolio, ranked #400.

Boothbay Fund Management first reported a position in DRUG in Q4 2021 and has held it in 9 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Boothbay Fund Management held 51,290 shares of Bright Minds Biosciences worth $3.74M as of Q1 2026.
  • Boothbay Fund Management bought 3,800 Bright Minds Biosciences shares in Q1 2026, an estimated $306K.
  • Bright Minds Biosciences made up 0.05% of Boothbay Fund Management's portfolio in Q1 2026, its #400 holding.
  • Boothbay Fund Management first reported a position in Bright Minds Biosciences in Q4 2021 and has held it in 9 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.